We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BioFire Diagnostics

BioFire Diagnostics, a subsidiary of bioMérieux SA, offers easy-to-use clinical molecular diagnostic solutions based ... read more Featured Products: More products

Download Mobile App




Enterovirus D68 Genome Sequenced

By LabMedica International staff writers
Posted on 11 Nov 2014
Print article
BioFire Diagnostics\' FilmArray System, a multiplex polymerase chain diagnostic platform
The FilmArray System, a multiplex polymerase chain diagnostic platform (Photo courtesy of BioFire Diagnostics owned by Biomerieux)
In recent months, the rare Enterovirus D68 (EV-D68) has spread rapidly across North America and caused severe respiratory illness in young children, with some requiring hospitalization.

Routine laboratory tests cannot identify specific Enterovirus and most hospitals and clinics can only perform tests to determine if a patient has a virus that fits broadly into the Enterovirus/rhinovirus category. As only specialized laboratories can identify the virus, merely 594 cases of EV-D68 infection have been officially confirmed in 43 US states and the District of Columbia.

Scientists at the Washington University School of Medicine (St. Louis, MO, USA) analyzed 14 patient samples testing positive for Enterovirus/rhinovirus. They determined the complete coding sequence of one strain from St. Louis by using high-throughput sequencing of nucleic acid from a clinical sample. To evaluate the sequence diversity in EV-D68 strains circulating in the St. Louis metropolitan area, they also generated partial-genome sequences from eight more EV-D68–positive clinical samples from the immediate area.

Residual material from a subset of nasopharyngeal specimens positive for Enterovirus/rhinovirus that had been tested by the BioFire FilmArray Respiratory Panel (BioFire Diagnostics; Salt Lake City, UT, USA) were selected for high-throughput sequencing. Total nucleic acid was extracted from clinical samples by using NucliSENS easyMAG (bioMérieux; Marcy l'Etoile, France) and used to make dual-indexed sequencing libraries. Enterovirus/rhinovirus sequences were enriched by using a NimbleGen custom sequence capture reagent (Roche/NimbleGen; Madison, WI, USA), which as of February 2014 was selective for all complete Enterovirus and rhinovirus genomes in the GenBank. Sequence data were generated on a HiSeq 2500 (Illumina; San Diego, CA, USA).

Of the 14 patient samples tested, nine were identified as infected with EV-D68 and the remaining five samples were other respiratory viruses. Seven of the nine patients with the EV-D68 strain had severe disease that required admission to the pediatric intensive care unit. The remaining two had moderate symptoms resulting in general hospital admission. Of the five patients with other viruses, three were classified with severe disease. The only two patients discharged home with mild disease did not have the EV-D68 strain.

Gregory A. Storch, MD, a professor of Pediatrics and senior author of the study said, “Having the DNA sequence of this virus enables additional investigative studies. It can be used to create better diagnostic tests. It also may help us understand why this epidemic seems to be producing severe and unusual disease, and why it's spreading more extensively than in the past." The study was published on October 28, 2014, in the journal Emerging Infectious Diseases.

Related Links:

Washington University School of Medicine
BioFire Diagnostics
BioMérieux


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
New
Tabletop Centrifuge
Mikro 185
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.